Clinical significance of TP53 mutation in myeloma

被引：113

作者：

Chng, W. J. ^{[1
]}

Price-Troska, T.

Gonzalez-Paz, N.

Van Wier, S.

Jacobus, S.

Blood, E.

Henderson, K.

Oken, M.

Van Ness, B.

Greipp, P.

Rajkumar, S. V.

Fonseca, R.

机构：

[1] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA

[2] Mayo Clin, Div Hematol, Rochester, MI USA

[3] Dana Farber Canc Inst, Eastern Cooperat Oncol Grp Stat Ctr, Boston, MA 02115 USA

[4] N Mem Canc Ctr, Dept Oncol, Minneapolis, MN USA

[5] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA

来源：

LEUKEMIA | 2007年 / 21卷 / 03期

关键词：

D O I：

10.1038/sj.leu.2404524

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：582 / 584

页数：3

共 8 条

[1] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].

Bischoff, JR ;

Kim, DH ;

Williams, A ;

Heise, C ;

Horn, S ;

Muna, M ;

Ng, L ;

Nye, JA ;

SampsonJohannes, A ;

Fattaey, A ;

McCormick, F .

SCIENCE, 1996, 274 (5286) :373-376

[2] Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].

Fonseca, R ;

Blood, E ;

Rue, M ;

Harrington, D ;

Oken, MM ;

Kyle, RA ;

Dewald, GW ;

Van Ness, B ;

Van Wier, SA ;

Henderson, KJ ;

Bailey, RJ ;

Greipp, PR .

BLOOD, 2003, 101 (11) :4569-4575

[3]

Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008-5472.CAN-03-2876

[4] International staging system for multiple myeloma [J].

Greipp, PR ;

San Miguel, J ;

Durie, BGM ;

Crowley, JJ ;

Barlogie, B ;

Bladé, J ;

Boccadoro, M ;

Child, JA ;

Harousseau, JL ;

Kyle, RA ;

Lahuerta, JJ ;

Ludwig, H ;

Morgan, G ;

Powles, R ;

Shimizu, K ;

Shustik, C ;

Sonneveld, P ;

Tosi, P ;

Turesson, I ;

Westin, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420

[5] ONYX-015: Clinical data are encouraging [J].

Kirn, D ;

Hermiston, T ;

McCormick, F .

NATURE MEDICINE, 1998, 4 (12) :1341-1342

[6] Phase 1, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer [J].

Tolcher, AW ;

Hao, D ;

de Bono, J ;

Miller, A ;

Patnaik, A ;

Hammond, LA ;

Smetzer, L ;

Hood, JV ;

Merritt, J ;

Rowinsky, EK ;

Takimoto, C ;

Von Hoff, D ;

Eckhardt, SG .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2052-2058

[7] Live or let die: The cell's response to p53 [J].

Vousden, KH ;

Lu, X .

NATURE REVIEWS CANCER, 2002, 2 (08) :594-604

[8]

ZHANG WW, 1994, CANCER GENE THER, V1, P5

← 1 →